Hyperpolarized 13C lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8607-8615

  Albers, Mark J ^a   Bok, Robert ^a   Chen, Albert P ^a   Cunningham, Charles H ^b   Zierhut, Matt L ^a   Zhang, Vickie Yi ^a   Kohler, Susan J ^c   Tropp, James ^d   Hurd, Ralph E ^d   Yen, Yi Fen ^d   Nelson, Sarah J ^a   Vigneron, Daniel B ^a   Kurhanewicz, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNION COLLEGE   (United States)

^d GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CARBON 13; LACTIC ACID; PYRUVIC ACID; CARBON; PYRUVIC ACID DERIVATIVE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERPOLARIZATION; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; DISEASE MODEL; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ALANINE; ANIMALS; CARBON ISOTOPES; DISEASE MODELS, ANIMAL; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; PYRUVATES; TUMOR MARKERS, BIOLOGICAL;

EID: 54249093810     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0749     Document Type: Article

References (41)

1. Carroll PR. Early stage prostate cancer - do we have a problem with over-detection, overtreatment or both? J Urol 2005;173:1061-2.
2. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-3.
3. Stamey TA. Cancer of the prostate: an analysis of some important contributions and dilemmas. Mono Urol 1982;3:67-94.
4. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
5. Hasumi M, Suzuki K, Taketomi A, et al. The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003;23:4223-7.
6. Portalez D, Malavaud B, Herigault G, et al. [Predicting prostate cancer with dynamic endorectal coil MR and proton spectroscopic MR imaging]. J Radiol 2004;85:1999-2004.
7. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213:473-80.
8. Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005;24:523-30.
9. Vilanova JC, Barcelo J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom Imaging 2007;32:253-61.
10. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4.
11. YuKK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-8.
12. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238:597-603.
13. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115-38.
14. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-14.
15. 13P magnetic resonance spectroscopy. J Urol 1993;150:2019-24.
16. 1H HR-MAS spectroscopy. Magn Reson Med 2006;55:1257-64.
17. 1H HR-MAS; spectroscopy of biopsy tissues. Magn Reson Med 2008;60:510-6.
18. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
19. Costello LC, Franklin RB. 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005;280:1-8.
20. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-53.
21. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015-24.
22. Warburg O, Wind F, Negelein E. Uber den Stoffwechsel von Tumouren im Korper. Klin Woch 1926;5:829-32.
23. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
24. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006;66:5216-23.
25. Oyama N, Akino H, KanamaruH, Okada K. [Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer]. Nippon Rinsho 1998;56:2052-5.
26. KanamaruH, Oyama N, Akino H, Okada K. [Evaluation of prostate cancer using FDG-PET]. Hinyokika Kiyo 2000;46:851-3.
27. +-dependent malic enzyme. J Biol Chem 1984;259:6215-21.
28. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-50.
29. Nelson SJ, Vigneron DB, Star-Lack J, Kurhanewicz J. High spatial resolution and speed in MRSI. NMR Biomed 1997;10:411-22.
30. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158-63.
31. Kohler SJ, Yen Y, Wolber J, et al. In vivo (13)carbon metabolic imaging at 3T with hyperpolarized (13)C-1-pyruvate. Magn Reson Med 2007;58:65-9.
32. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007;58:1099-106.
33. 13C. Br J Radiol 2003;76:S118-27.
34. 13C imaging - a new diagnostic platform. Eur Radiol 2006;16:57-67.
35. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006;66:10855-60.
36. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized (13)C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.
37. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
38. Cunningham CH, Chen AP, Albers MJ, et al. Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized (13)C. J Magn Reson 2007;187:357-62.
39. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
40. Diggle PJ, Liang K-Y, Zeger SL. Parametric models for covariance structure. New York: Oxford University Press; 1994. p. 78-116.
41. Lin RY, Vera JC, Chaganti RS, Golde DW. Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem 1998;273:28959-65.